期刊
MOLECULAR PHARMACOLOGY
卷 88, 期 2, 页码 238-244出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.115.098541
关键词
-
资金
- NIDA NIH HHS [Y1-DA1101] Funding Source: Medline
6-Alkoxy-5-aryl-3-pyridincarboxamides, including the brain-penetrant compound 14g [5-(4-chlorophenyl)-6-(cyclopropylmethoxy)-N-[(1R,2R)-2-hydroxy-cyclohexyl]-3-pyridinecarboxamide] and its peripherally restricted analog 14h [5-(4-chlorophenyl)N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2-methoxyethoxy)-3-pyridinecarboxamide], have been recently introduced as selective, high-affinity antagonists of the human cannabinoid-1 receptor (hCB(1)R). Binding analyses revealed two orders of magnitude lower affinity of these compounds for mouse and rat versus human CB1R, whereas the affinity of rimonabant is comparable for all three CB(1)Rs. Modeling of ligand binding to CB1R and binding assays with native and mutant (Ile105Met) hCB(1)Rs indicate that the Ile105 to Met mutation in rodent CB(1)Rs accounts for the species-dependent affinity of 14g and 14h. Our work identifies Ile105 as a new pharmacophore component for developing better hCB(1)R antagonists and invalidates rodent models for assessing the antiobesity efficacy of 14g and 14h.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据